The 8 analysts offering 12-month price forecasts for Seres Therapeutics Inc have a median target of 17.50, with a high estimate of 32.00 and a low estimate of 7.00. The median estimate represents a +132.71% increase from the last price of 7.52.
The current consensus among 9 polled investment analysts is to Buy stock in Seres Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.44
Reporting Date Mar 09
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.